Show simple item record

dc.contributor.authorLopez, Daniel 
dc.date.accessioned2022-05-23T10:21:19Z
dc.date.available2022-05-23T10:21:19Z
dc.date.issued2022-01-28
dc.identifier.citationFront Immunol. 2022 Jan 28;13:832889.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14452
dc.description.abstractThe potential effect of emerging SARS-CoV-2 variants on vaccine efficacy is an issue of critical importance. In this study, the possible impact of mutations that facilitate virus escape from the cytotoxic and the helper cellular immune responses in the new SARS-CoV-2 Omicron variant of concern was analyzed for the 551 and 41 most abundant HLA class I and II alleles, respectively. Computational prediction showed that almost all of these 592 alleles, which cover >90% of the human population, contain enough epitopes without escape mutations in the emerging SARS-CoV-2 Omicron variant of concern. These data suggest that both cytotoxic and helper cellular immune protection elicited by currently licensed vaccines are virtually unaffected by the highly contagious SARS-CoV-2 Omicron variant of concern.es_ES
dc.description.sponsorshipThis research was supported by grant MPY 388/18 of “Acción Estratégica en Salud” from the ISCIII.es_ES
dc.language.isoenges_ES
dc.publisherFrontiers Media es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHLA class 1es_ES
dc.subjectHLA class 2es_ES
dc.subjectSARS-CoV-2es_ES
dc.subjectEscape mutantes_ES
dc.subjectVaccinees_ES
dc.subject.meshCOVID-19es_ES
dc.subject.meshEpitopes, T-Lymphocyte es_ES
dc.subject.meshHistocompatibility Antigens Class I es_ES
dc.subject.meshHistocompatibility Antigens Class II es_ES
dc.subject.meshHumans es_ES
dc.subject.meshImmunity, Cellular es_ES
dc.subject.meshImmunogenicity, Vaccinees_ES
dc.subject.meshMutation es_ES
dc.subject.meshSARS-CoV-2es_ES
dc.subject.meshSpike Glycoprotein, Coronaviruses_ES
dc.titlePredicted HLA Class I and Class II Epitopes From Licensed Vaccines Are Largely Conserved in New SARS-CoV-2 Omicron Variant of Concernes_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID35154154es_ES
dc.format.volume13es_ES
dc.format.page832889es_ES
dc.identifier.doi10.3389/fimmu.2022.832889es_ES
dc.contributor.funderInstituto de Salud Carlos III es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn1664-3224es_ES
dc.relation.publisherversionhttps://doi.org/10.3389/fimmu.2022.832889es_ES
dc.identifier.journalFrontiers in Immunologyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES
dc.relation.projectFISinfo:eu-repo/grantAgreement/ES/MPY388/18es_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional